Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022

Rothschedl, E. and Wolf, S. (2022): Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022. Oncology Fact Sheet Nr. 101.

[thumbnail of Oncology Fact Sheet Nr.101_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
106kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 101
Deposited on:	26 Jul 2022 14:53
Last Modified:	22 Nov 2022 18:13

Repository Staff Only: item control page